PVM
ACTU

Palogic Value Management’s Actuate Therapeutics ACTU Stock Holding History

Palogic Value Management’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$153K Hold
100,000
– – 0.05% 191
2026
Q1 		$274K Buy
+100,000
New +$414K 0.12% 154

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return
AIM
ABS Investment Management Greenwich, Connecticut $159M AUM

Palogic Value Management's ACTU Position: Q2 2026 in Review

Palogic Value Management held its Actuate Therapeutics (ACTU) position steady in Q2 2026 at 100,000 shares worth $153K. The position accounts for 0.05% of the portfolio, ranked #191.

Palogic Value Management first reported a position in ACTU in Q1 2026 and has held it in 2 quarters since. The position peaked at $274K in Q1 2026. 64 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Palogic Value Management held 100,000 shares of Actuate Therapeutics worth $153K as of Q2 2026.
  • Palogic Value Management left its Actuate Therapeutics share count unchanged in Q2 2026.
  • Actuate Therapeutics made up 0.05% of Palogic Value Management's portfolio in Q2 2026, its #191 holding.
  • Palogic Value Management first reported a position in Actuate Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Palogic Value Management's Actuate Therapeutics position peaked at $274K in Q1 2026.
  • 64 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Palogic Value Management's 13F filing for Q2 2026, filed 14 Aug 2026.